Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$0.93 - HK$7.95
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$1.76B
Enterprise ValueHK$970.39
Total Cash (Recent Filing)HK$1.38B
Total Debt (Recent Filing)HK$258.36M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)HK$300.12M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth indicates continued demand for the company’s cardiovascular intervention products. If maintained, expanding procedure volumes and commercial reach could provide a foundation for operating leverage and eventual profitability.
Gross MarginA solid gross margin suggests the product portfolio retains meaningful economic value and pricing capacity. This provides potential to absorb research, commercial, and manufacturing costs, although profitability still depends on improving operating efficiency.
Recurring Procedure DemandThe business benefits from demand linked to ongoing cardiovascular procedures, with single-use consumables creating repeat purchasing opportunities. This procedure-based model can support durable revenue visibility as hospitals continue treating patients.
Bears Say
Persistent LossesRevenue growth has not translated into sustainable earnings, and losses widened versus 2024. Continued operating losses weaken internal funding capacity and increase dependence on external financing or future margin improvement.
High LeverageThe sharp increase in leverage materially raises refinancing and financial-flexibility risk. High debt relative to equity is especially burdensome while the company remains loss-making, potentially restricting investment in product development and commercial expansion.
Negative Cash GenerationNegative operating and free cash flow show that the company is not yet consistently self-funding its operations and investment needs. Persistent cash burn could increase reliance on debt or equity financing, particularly alongside elevated leverage.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$0.93 and its highest was HK$7.95 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$1.76B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Aug 26, 2026 which is in 3 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―